Josefin Sundh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Josefin Sundh has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Magnus Ekström
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine, Allergology and Palliative Medicine, Lund, Sweden
19 shared publications Christer Janson
12Uppsala University, Uppsala, Sweden
17 shared publications- Christer Janson
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
13 shared publications - Andreas Palm
Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University
12 shared publications - Björn Ställberg
Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University
12 shared publications Mikael Hasselgren
Region Värmland, Karlstad, Sweden
12 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- p. 1-8
End-of-life care of patients with amyotrophic lateral sclerosis and home mechanical ventilation: the national population-based DISCOVERY study
Amyotrophic lateral sclerosis (ALS) is a progressive and incurable motor neuron disease characterized by degeneration of upper and lower motor neurons, leading to progressive muscle weakness, disab...
- 21 October 2026
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- p. 1-8
Open AccessEnd-of-life care of patients with amyotrophic lateral sclerosis and home mechanical ventilation: the national population-based DISCOVERY study
Amyotrophic lateral sclerosis (ALS) is a progressive and incurable motor neuron disease characterized by degeneration of upper and lower motor neurons, leading to progressive muscle weakness, disab...
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , OA1264
Late Breaking Abstract - Metoprolol in Chronic Obstructive Pulmonary Disease without Cardiovascular Disease - a randomized controlled trial
Background: Beta-blockers may improve outcomes in patients with chronic obstructive pulmonary disease (COPD) without cardiovascular disease, but randomized trials have been inconclusive. Methods: We conducted a multicenter, open-label, pragmatic, phase 4 randomized trial. Patients 40 years of age or older with spirometry-confirmed COPD, sinus rhythm, and no clinical cardiovascular disease were assigned in a 1:1 ratio to receive metoprolol, target dose 100 mg daily, in addition to standard care, or to standard care alone. The primary end point was the time to the first occurrence of a COPD exacerbation, cardiovascular event, or death during 1 year of follow-up. Outcomes were adjudicated. Results: A total of 1695 patients underwent randomization; the mean age was 70 years and 62% were women. The primary end point occurred in 27% of patients assigned to metoprolol and in 30% assigned to standard care (hazard ratio 0.87; 95% confidence interval (CI) 0.73-1.05, P = 0.14). The corresponding hazard ratios were 0.88 (95% CI, 0.72 to 1.08) for COPD exacerbations, 0.73 (95% CI, 0.48 to 1.11) for cardiovascular events, 0.92 (95% CI, 0.48 to 1.77) for death, and 0.87 (95% CI, 0.58 to 1.28) for hospitalized exacerbations. In a prespecified subgroup analysis the hazard ratio for the primary end point was 0.70 (95% CI, 0.56 to 0.88) among women and 1.28 (95% CI, 0.94 to 1.74) among men (P for interaction<0.01). Conclusions: Among patients with COPD and no clinical cardiovascular disease, metoprolol did not significantly reduce the incidence of a composite of exacerbations, cardiovascular events, or death.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , OA1264
Late Breaking Abstract - Metoprolol in Chronic Obstructive Pulmonary Disease without Cardiovascular Disease - a randomized controlled trial
Background: Beta-blockers may improve outcomes in patients with chronic obstructive pulmonary disease (COPD) without cardiovascular disease, but randomized trials have been inconclusive. Methods: We conducted a multicenter, open-label, pragmatic, phase 4 randomized trial. Patients 40 years of age or older with spirometry-confirmed COPD, sinus rhythm, and no clinical cardiovascular disease were assigned in a 1:1 ratio to receive metoprolol, target dose 100 mg daily, in addition to standard care, or to standard care alone. The primary end point was the time to the first occurrence of a COPD exacerbation, cardiovascular event, or death during 1 year of follow-up. Outcomes were adjudicated. Results: A total of 1695 patients underwent randomization; the mean age was 70 years and 62% were women. The primary end point occurred in 27% of patients assigned to metoprolol and in 30% assigned to standard care (hazard ratio 0.87; 95% confidence interval (CI) 0.73-1.05, P = 0.14). The corresponding hazard ratios were 0.88 (95% CI, 0.72 to 1.08) for COPD exacerbations, 0.73 (95% CI, 0.48 to 1.11) for cardiovascular events, 0.92 (95% CI, 0.48 to 1.77) for death, and 0.87 (95% CI, 0.58 to 1.28) for hospitalized exacerbations. In a prespecified subgroup analysis the hazard ratio for the primary end point was 0.70 (95% CI, 0.56 to 0.88) among women and 1.28 (95% CI, 0.94 to 1.74) among men (P for interaction<0.01). Conclusions: Among patients with COPD and no clinical cardiovascular disease, metoprolol did not significantly reduce the incidence of a composite of exacerbations, cardiovascular events, or death.
- Open Access
- 28 August 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Fall-related injuries in long-term oxygen therapy: Incidence and predictive factors
Introduction: Fall-related injuries are a common cause of morbidity and impaired quality of life among patients with severe respiratory disease. Use of long-term oxygen therapy (LTOT) may be associated with a further increased risk. Methods: This was a longitudinal study of patients starting LTOT between 2006 and 2023 in the Swedish DISCOVERY cohort. Rates of healthcare contact due to three types of fall-related injuries (distal radius fracture, hip fracture, and skull trauma) were compared to those of age- and sex-matched population controls using nationwide registries. For patients on LTOT, pre-identified potentially predictive factors were analyzed against a composite outcome of any fall-related injury using Cox and Fine-Gray regression, independently, adjusting for age, sex and Charlson Comorbidity Index (CCI), and in a joint model adjusting for all predictive factors. Results: A total 16,915 patients with LTOT (mean age 76±9 years, 57% female, 63% underlying COPD) and an equal number of matched controls were included. Compared with controls, LTOT patients had increased overall rates of both hospitalizations (15.5 vs 7.3 per 100 patient-years) and outpatient (16.9 vs 13.6 per 100 patient-years) healthcare contacts due to fall-related injuries, driven by hip fractures and skull trauma, whereas distal radius fractures were more common among patients without LTOT. The strongest independent predictive factors for fall-related injury during LTOT were history of previous fall-related injury (HR1.8; 95% confidence interval 1.7-2.0) and increased CCI. The overall predictive capability of the model was poor (C-statistic 0.65). Conclusion: Patients on LTOT have a high rate of health care contacts due to hip fractures and skull trauma, but whether this increase is caused by use of oxygen equipment or underlying frailty remains unknown. While individual falls were difficult to predict, indicators such as previous fall injury and comorbidities, may inform optimized follow-up and interventions aimed at mitigating risk.
- 28 August 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Open AccessFall-related injuries in long-term oxygen therapy: Incidence and predictive factors
Introduction: Fall-related injuries are a common cause of morbidity and impaired quality of life among patients with severe respiratory disease. Use of long-term oxygen therapy (LTOT) may be associated with a further increased risk. Methods: This was a longitudinal study of patients starting LTOT between 2006 and 2023 in the Swedish DISCOVERY cohort. Rates of healthcare contact due to three types of fall-related injuries (distal radius fracture, hip fracture, and skull trauma) were compared to those of age- and sex-matched population controls using nationwide registries. For patients on LTOT, pre-identified potentially predictive factors were analyzed against a composite outcome of any fall-related injury using Cox and Fine-Gray regression, independently, adjusting for age, sex and Charlson Comorbidity Index (CCI), and in a joint model adjusting for all predictive factors. Results: A total 16,915 patients with LTOT (mean age 76±9 years, 57% female, 63% underlying COPD) and an equal number of matched controls were included. Compared with controls, LTOT patients had increased overall rates of both hospitalizations (15.5 vs 7.3 per 100 patient-years) and outpatient (16.9 vs 13.6 per 100 patient-years) healthcare contacts due to fall-related injuries, driven by hip fractures and skull trauma, whereas distal radius fractures were more common among patients without LTOT. The strongest independent predictive factors for fall-related injury during LTOT were history of previous fall-related injury (HR1.8; 95% confidence interval 1.7-2.0) and increased CCI. The overall predictive capability of the model was poor (C-statistic 0.65). Conclusion: Patients on LTOT have a high rate of health care contacts due to hip fractures and skull trauma, but whether this increase is caused by use of oxygen equipment or underlying frailty remains unknown. While individual falls were difficult to predict, indicators such as previous fall injury and comorbidities, may inform optimized follow-up and interventions aimed at mitigating risk.
- Open Access
- 24 July 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Home mechanical ventilation for amyotrophic lateral sclerosis–a national study of survival and treatment trends across 27 years
Rationale: Home mechanical ventilation (HMV) improves survival in Amyotrophic lateral sclerosis (ALS) and may be provided non-invasively (NIV) or invasively (IV). While NIV is guideline-recommended, the role of IV remains controversial, and data on long-term outcomes and NIV-to-IV transitions are limited. Objectives: To examine survival across HMV strategies in people with ALS (pwALS) in Sweden over 27 years, factors associated with IV initiation, temporal trends in IV use and survival, and regional variation in IV utilisation. Methods: A longitudinal cohort study of pwALS in the Swedish National Registry of Ventilatory Failure (Swedevox) 1996–2022, cross-linked with national registries. Factors associated with mortality and treatment patterns were assessed using multivariable regression models. Results: Among 1,360 pwALS, initial NIV was most common (92%), followed by IV (5%) and NIV-to-IV transitions (3%). Most IV initiations were non-elective (77% vs. 18% NIV, p < 0.001). NIV-to-IV transitions occurred mainly in metropolitan areas (OR 5.11; 95% CI 2.30–11.4). Median survival differed across observed treatment pathways (p < 0.001): 1.7 years with NIV, 4.9 years with IV, and 6.5 years with NIV-to-IV. Mortality was associated with higher age (aHR 1.33 per decade; 95% CI 1.26–1.41), female sex (aHR 1.15; 95% CI 1.02–1.29), and acute initiation (aHR 1.26; 95% CI 1.08–1.47). Longer time from diagnosis to NIV initiation was associated with reduced mortality risk (aHR 0.58 per year; 95% CI 0.55–0.62). Over time, patients initiated HMV at older age with better lung function and lower PaCO2 values among those with available measurements, whereas overall survival remained unchanged. Conclusion: Patients receiving IV had longer observed survival, likely reflecting the benefits of a secured airway as well as patient selection and underlying disease trajectory. Most IV initiations were unplanned. Over three decades, HMV was initiated in older patients at an earlier stage of respiratory decline, but overall survival remained unchanged. IV use increased with marked regional variation.
- 24 July 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Open AccessHome mechanical ventilation for amyotrophic lateral sclerosis–a national study of survival and treatment trends across 27 years
Rationale: Home mechanical ventilation (HMV) improves survival in Amyotrophic lateral sclerosis (ALS) and may be provided non-invasively (NIV) or invasively (IV). While NIV is guideline-recommended, the role of IV remains controversial, and data on long-term outcomes and NIV-to-IV transitions are limited. Objectives: To examine survival across HMV strategies in people with ALS (pwALS) in Sweden over 27 years, factors associated with IV initiation, temporal trends in IV use and survival, and regional variation in IV utilisation. Methods: A longitudinal cohort study of pwALS in the Swedish National Registry of Ventilatory Failure (Swedevox) 1996–2022, cross-linked with national registries. Factors associated with mortality and treatment patterns were assessed using multivariable regression models. Results: Among 1,360 pwALS, initial NIV was most common (92%), followed by IV (5%) and NIV-to-IV transitions (3%). Most IV initiations were non-elective (77% vs. 18% NIV, p < 0.001). NIV-to-IV transitions occurred mainly in metropolitan areas (OR 5.11; 95% CI 2.30–11.4). Median survival differed across observed treatment pathways (p < 0.001): 1.7 years with NIV, 4.9 years with IV, and 6.5 years with NIV-to-IV. Mortality was associated with higher age (aHR 1.33 per decade; 95% CI 1.26–1.41), female sex (aHR 1.15; 95% CI 1.02–1.29), and acute initiation (aHR 1.26; 95% CI 1.08–1.47). Longer time from diagnosis to NIV initiation was associated with reduced mortality risk (aHR 0.58 per year; 95% CI 0.55–0.62). Over time, patients initiated HMV at older age with better lung function and lower PaCO2 values among those with available measurements, whereas overall survival remained unchanged. Conclusion: Patients receiving IV had longer observed survival, likely reflecting the benefits of a secured airway as well as patient selection and underlying disease trajectory. Most IV initiations were unplanned. Over three decades, HMV was initiated in older patients at an earlier stage of respiratory decline, but overall survival remained unchanged. IV use increased with marked regional variation.
- Open Access
- 24 April 2026
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 13 (1)
Associations between respiratory health, reported traffic, and occupational-related exposure
Rapid urbanisation over the past century has led to increased traffic density and higher levels of ambient air pollutants. We aimed to investigate whether the prevalence of respiratory symptoms, asthma, and chronic bronchitis increases with the level of self-reported exposure to traffic and occupational-related pollution. The study population comprised 25,889 general population subjects ages 16–75 years participating in the Swedish part of the GA2LEN study. Data were collected in the cities of Umeå, Uppsala, Stockholm, and Gothenburg. Self-reported data on disturbance of fumes from traffic in the residential area or occupational exposure to gas, dust, or smoke, as well as on patient demographics, respiratory symptoms, asthma and chronic bronchitis, were obtained from questionnaires. The prevalence of respiratory symptoms, asthma, and chronic bronchitis was higher both among participants reporting traffic-related exposure and those with a history of occupational exposure to fumes, smoke, and dust than among those unexposed; (wheeze 27 vs 13%), nocturnal cough (35 vs 22%), asthma (11 vs 6%) and chronic bronchitis (22 vs 8%); all p < 0.0001. When combining traffic and occupational exposure, the highest prevalence was found amongst those exposed to both. Associations with occupational exposure were generally stronger in women, and those with traffic exposure were stronger in men. In this large population-based sample, self-reported residential traffic exposure and occupational exposure to dust, fumes, or smoke were associated with increased prevalence of respiratory symptoms, asthma, and chronic bronchitis. Although causality cannot be inferred, these findings underscore the importance of assessing environmental and occupational exposures in evaluating respiratory health.
- 24 April 2026
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 13 (1)
Open AccessAssociations between respiratory health, reported traffic, and occupational-related exposure
Rapid urbanisation over the past century has led to increased traffic density and higher levels of ambient air pollutants. We aimed to investigate whether the prevalence of respiratory symptoms, asthma, and chronic bronchitis increases with the level of self-reported exposure to traffic and occupational-related pollution. The study population comprised 25,889 general population subjects ages 16–75 years participating in the Swedish part of the GA2LEN study. Data were collected in the cities of Umeå, Uppsala, Stockholm, and Gothenburg. Self-reported data on disturbance of fumes from traffic in the residential area or occupational exposure to gas, dust, or smoke, as well as on patient demographics, respiratory symptoms, asthma and chronic bronchitis, were obtained from questionnaires. The prevalence of respiratory symptoms, asthma, and chronic bronchitis was higher both among participants reporting traffic-related exposure and those with a history of occupational exposure to fumes, smoke, and dust than among those unexposed; (wheeze 27 vs 13%), nocturnal cough (35 vs 22%), asthma (11 vs 6%) and chronic bronchitis (22 vs 8%); all p < 0.0001. When combining traffic and occupational exposure, the highest prevalence was found amongst those exposed to both. Associations with occupational exposure were generally stronger in women, and those with traffic exposure were stronger in men. In this large population-based sample, self-reported residential traffic exposure and occupational exposure to dust, fumes, or smoke were associated with increased prevalence of respiratory symptoms, asthma, and chronic bronchitis. Although causality cannot be inferred, these findings underscore the importance of assessing environmental and occupational exposures in evaluating respiratory health.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-11
Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts
Purpose: The study aimed to investigate the associations between impaired spirometry such as obstructive pattern and preserved ratio impaired spirometry (PRISm) and occurrent cardiovascular events and deaths in patients with acute myocardial infarction. Patients and Methods: Cohort study of 517 patients with age ≥ 40 years and ≥ 10 pack-years of smoking, hospitalized for myocardial infarction at eight sites in Sweden and the United Kingdom. The Vitalograph® COPD-6 device was used to assess the ratio of forced expiratory volume in 1 and 6 seconds (FEV1/FEV6) and FEV1 as a percentage of the predicted value (FEV1%pred). Obstructive pattern was defined as FEV1/FEV6 < 0.7, PRISm as FEV1/FEV6 > 0.7 and FEV1%pred < 80, and normal findings as FEV1/FEV6 ≥ 0.7 and FEV1%pred ≥ 80. Follow-up data were obtained from national registers or follow-up visits. Multivariable Cox regression was used to analyze the associations of obstructive pattern and PRISm with the incidence of acute ischemic cardiovascular events or major adverse cardiovascular events (MACE), respectively, within one year. Results: Obstructive pattern was found in 95 (18%), PRISm in 192 (37%) and normal spirometry in 230 (45%) patients. A cardiovascular event occurred in 21 (4%) and MACE in 28 (5%). Compared with normal spirometry, PRISm was independently associated with both new cardiovascular events (HR (95% CI) 3.44 (1.07– 11.0)) and MACE (4.94 (1.63 to 15.0)), and obstructive pattern with MACE (3.87 (1.08– 13.8)). Further adjustment for cardiac or COPD treatment did not substantially change the results. Conclusion: About half of patients with acute myocardial infarction and a ≥ 10 pack-year smoking history have abnormal spirometry findings. Both obstructive pattern and PRISm are independently associated with increased risk for MACE within one year. We suggest that spirometry should be considered as a routine assessment in patients with smoking history and recent myocardial infarction. Plain Language Summary: Impaired spirometry such as obstructive pattern as in chronic obstructive pulmonary disease (COPD) and preserved ratio impaired spirometry (PRISm) are associated with increased risk of mortality in the general populationThe present study investigated the prevalence and associations of obstructive pattern and PRISm with and occurrent cardiovascular events and deaths in patients with acute myocardial infarction, in cohorts from Sweden and the United KingdomWe found that about half of patients with acute myocardial infarction and a ≥ 10 pack-year smoking history have abnormal spirometry findingsIn patients with acute myocardial infarction and a ≥ 10 pack-year smoking history, obstructive pattern and PRISm are both associated with increased one-year risk of occurrent acute ischemic cardiovascular events and cardiovascular deaths
- 1 April 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-11
Open AccessPrognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts
Purpose: The study aimed to investigate the associations between impaired spirometry such as obstructive pattern and preserved ratio impaired spirometry (PRISm) and occurrent cardiovascular events and deaths in patients with acute myocardial infarction. Patients and Methods: Cohort study of 517 patients with age ≥ 40 years and ≥ 10 pack-years of smoking, hospitalized for myocardial infarction at eight sites in Sweden and the United Kingdom. The Vitalograph® COPD-6 device was used to assess the ratio of forced expiratory volume in 1 and 6 seconds (FEV1/FEV6) and FEV1 as a percentage of the predicted value (FEV1%pred). Obstructive pattern was defined as FEV1/FEV6 < 0.7, PRISm as FEV1/FEV6 > 0.7 and FEV1%pred < 80, and normal findings as FEV1/FEV6 ≥ 0.7 and FEV1%pred ≥ 80. Follow-up data were obtained from national registers or follow-up visits. Multivariable Cox regression was used to analyze the associations of obstructive pattern and PRISm with the incidence of acute ischemic cardiovascular events or major adverse cardiovascular events (MACE), respectively, within one year. Results: Obstructive pattern was found in 95 (18%), PRISm in 192 (37%) and normal spirometry in 230 (45%) patients. A cardiovascular event occurred in 21 (4%) and MACE in 28 (5%). Compared with normal spirometry, PRISm was independently associated with both new cardiovascular events (HR (95% CI) 3.44 (1.07– 11.0)) and MACE (4.94 (1.63 to 15.0)), and obstructive pattern with MACE (3.87 (1.08– 13.8)). Further adjustment for cardiac or COPD treatment did not substantially change the results. Conclusion: About half of patients with acute myocardial infarction and a ≥ 10 pack-year smoking history have abnormal spirometry findings. Both obstructive pattern and PRISm are independently associated with increased risk for MACE within one year. We suggest that spirometry should be considered as a routine assessment in patients with smoking history and recent myocardial infarction. Plain Language Summary: Impaired spirometry such as obstructive pattern as in chronic obstructive pulmonary disease (COPD) and preserved ratio impaired spirometry (PRISm) are associated with increased risk of mortality in the general populationThe present study investigated the prevalence and associations of obstructive pattern and PRISm with and occurrent cardiovascular events and deaths in patients with acute myocardial infarction, in cohorts from Sweden and the United KingdomWe found that about half of patients with acute myocardial infarction and a ≥ 10 pack-year smoking history have abnormal spirometry findingsIn patients with acute myocardial infarction and a ≥ 10 pack-year smoking history, obstructive pattern and PRISm are both associated with increased one-year risk of occurrent acute ischemic cardiovascular events and cardiovascular deaths
- Open Access
- 4 February 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Effect of HIgh-Flow Therapy in Long-Term Oxygen Therapy (HILOT): study protocol for a multicentre, registry-based, randomised clinical trial
Background: The use of high-flow oxygen therapy (HFOT) compared with standard low-flow oxygen therapy (LFOT) may improve outcomes in people with oxygen-dependent chronic respiratory failure (CRF). The primary aim of this multicentre trial was to evaluate HFOT in addition to LFOT, compared with regular LFOT in people with CRF due to chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). Methods: Registry-based randomised controlled trial (R-RCT) of people on LFOT for CRF due to COPD ( n = 270) and ILD ( n = 40), at ten Swedish secondary care centres within the Swedish Register for Respiratory Failure (Swedevox). People with ongoing LFOT are randomised in a 1:1 ratio to standard treatment with LFOT (control) or LFOT with added HFOT during nighttime and at the patient’s discretion daytime (intervention). HFOT is provided using the ResMed Lumis HFT system and the AcuCare HFNC Cannula. Primary outcome is time to first hospitalisation or death up to 1 year in people with COPD. Secondary outcomes include symptoms, health-related outcomes (HRQL), health-economics, adverse events, and to explore the effects of HFOT in people with CRF due to ILD. Outcome data will be obtained from national registries and from patient questionnaires at 3 and 12 months. Discussion: This R-RCT will combine the advantages of a prospective randomised trial and large clinical national registries to improve the evidence-based use of long-term oxygen therapy. Recruitment started in June 2024 and is ongoing. Trial registration: ClinicalTrials.gov, ID: NCT06247397. Registered 2024–02–07.
- 4 February 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessEffect of HIgh-Flow Therapy in Long-Term Oxygen Therapy (HILOT): study protocol for a multicentre, registry-based, randomised clinical trial
Background: The use of high-flow oxygen therapy (HFOT) compared with standard low-flow oxygen therapy (LFOT) may improve outcomes in people with oxygen-dependent chronic respiratory failure (CRF). The primary aim of this multicentre trial was to evaluate HFOT in addition to LFOT, compared with regular LFOT in people with CRF due to chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). Methods: Registry-based randomised controlled trial (R-RCT) of people on LFOT for CRF due to COPD ( n = 270) and ILD ( n = 40), at ten Swedish secondary care centres within the Swedish Register for Respiratory Failure (Swedevox). People with ongoing LFOT are randomised in a 1:1 ratio to standard treatment with LFOT (control) or LFOT with added HFOT during nighttime and at the patient’s discretion daytime (intervention). HFOT is provided using the ResMed Lumis HFT system and the AcuCare HFNC Cannula. Primary outcome is time to first hospitalisation or death up to 1 year in people with COPD. Secondary outcomes include symptoms, health-related outcomes (HRQL), health-economics, adverse events, and to explore the effects of HFOT in people with CRF due to ILD. Outcome data will be obtained from national registries and from patient questionnaires at 3 and 12 months. Discussion: This R-RCT will combine the advantages of a prospective randomised trial and large clinical national registries to improve the evidence-based use of long-term oxygen therapy. Recruitment started in June 2024 and is ongoing. Trial registration: ClinicalTrials.gov, ID: NCT06247397. Registered 2024–02–07.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 18, 1825-1834
No Improvement of Asthma Control Despite Changes in Pharmacological Treatment Patterns – 17 Years Follow Up
Asthma control is reported to be low, often based on cross-sectional studies. There have been only a few longitudinal studies following asthma patients. We have assessed asthma control and asthma treatment over 17 years in a cohort of asthma patients. Patients, 18–75 years, with doctor-diagnosed asthma were randomly selected from healthcare units in Sweden. They answered questionnaires about symptoms and pharmacological treatment in 2005, 2012, and 2022. This study includes participants completing the last follow-up (n=437). Optimal asthma control was defined as no nocturnal asthma symptoms, use of short-acting β2-agonist twice or less in the past week, and no exacerbations in the last six months. There was no difference in frequency of optimal asthma control (41.8% vs 40.5%, p=0.68). Inhaled corticosteroids (ICS) in combination with long-acting β2-agonists increased from 2005 to 2022 as regular maintenance treatment (40.3% vs 46.7%, p=0.009) and as reliever medicine (11.6% vs 18.9%, p<0.001). The overall use of reliever medicine more than twice in the past week did not change (48.3% vs 51.6%, p=0.24). The overall use of ICS decreased (78.0% vs 70.4%, p<0.001), as did the occurrence of having a written action plan (21.9% vs 10.4%, p<0.001). Optimal asthma control and lack of written action plans were related to discontinuation of ICS treatment. Non-optimal asthma control is common long after diagnosis. Discontinuation of ICS may sometimes be due to optimal asthma control and no need for treatment, but lack of written action plans increases the risk of inappropriate discontinuation.
- 1 December 2025
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 18, 1825-1834
Open AccessNo Improvement of Asthma Control Despite Changes in Pharmacological Treatment Patterns – 17 Years Follow Up
Asthma control is reported to be low, often based on cross-sectional studies. There have been only a few longitudinal studies following asthma patients. We have assessed asthma control and asthma treatment over 17 years in a cohort of asthma patients. Patients, 18–75 years, with doctor-diagnosed asthma were randomly selected from healthcare units in Sweden. They answered questionnaires about symptoms and pharmacological treatment in 2005, 2012, and 2022. This study includes participants completing the last follow-up (n=437). Optimal asthma control was defined as no nocturnal asthma symptoms, use of short-acting β2-agonist twice or less in the past week, and no exacerbations in the last six months. There was no difference in frequency of optimal asthma control (41.8% vs 40.5%, p=0.68). Inhaled corticosteroids (ICS) in combination with long-acting β2-agonists increased from 2005 to 2022 as regular maintenance treatment (40.3% vs 46.7%, p=0.009) and as reliever medicine (11.6% vs 18.9%, p<0.001). The overall use of reliever medicine more than twice in the past week did not change (48.3% vs 51.6%, p=0.24). The overall use of ICS decreased (78.0% vs 70.4%, p<0.001), as did the occurrence of having a written action plan (21.9% vs 10.4%, p<0.001). Optimal asthma control and lack of written action plans were related to discontinuation of ICS treatment. Non-optimal asthma control is common long after diagnosis. Discontinuation of ICS may sometimes be due to optimal asthma control and no need for treatment, but lack of written action plans increases the risk of inappropriate discontinuation.
- Open Access
- 15 November 2025
- Published by Springer Nature in Respiratory Research
- Vol. 26 (1) , 321
Similar risk of hospitalization and mortality for patients continuing and discontinuing LTOT
Introduction: While the characteristics and medical management of patients treated with long-term oxygen therapy (LTOT) have transformed during the last decades, the evidence base for LTOT itself remains largely unchanged. This study aimed to compare the risk of hospitalization and death among hypoxemic patients discontinuing LTOT, with that of controls continuing therapy. Methods: This was a retrospective observational study of patients with LTOT included in the DISCOVERY cohort, using elements of target trial emulation. Patients who fulfilled LTOT criteria but discontinued treatment with LTOT within 90 days of initiation, not due to improving oxygenation or change of treatment modality, were identified. The risk of hospitalization and death as a composite outcome, and the risks of individual outcomes of hospitalization and death, were compared with age-, sex- and disease type-matched controls who continued LTOT, using Cox regression adjusted for confounders. Results: In total, 79 patients discontinuing LTOT and 395 controls were analyzed, both groups with a mean age of 73 (SD ± 11) years, 72% females, 65% underlying COPD. In adjusted Cox regression models, discontinuing LTOT was not associated with an increased risk of hospitalization or death (hazard ratio (HR) 1.0 95% Confidence interval (CI) 0.78–1.3), hospitalization (HR 0.99 95% CI 0.75–1.3), or death (HR 0.79 95% CI 0.61-1.0). Conclusion: In this study, patients fulfilling LTOT initiation criteria who discontinued therapy were not found to be at an increased risk of hospitalization or death, suggesting equipoise for a randomized trial of LTOT discontinuation or non-initiation in selected patient groups.
- 15 November 2025
- Published by Springer Nature in Respiratory Research
- Vol. 26 (1) , 321
Open AccessSimilar risk of hospitalization and mortality for patients continuing and discontinuing LTOT
Introduction: While the characteristics and medical management of patients treated with long-term oxygen therapy (LTOT) have transformed during the last decades, the evidence base for LTOT itself remains largely unchanged. This study aimed to compare the risk of hospitalization and death among hypoxemic patients discontinuing LTOT, with that of controls continuing therapy. Methods: This was a retrospective observational study of patients with LTOT included in the DISCOVERY cohort, using elements of target trial emulation. Patients who fulfilled LTOT criteria but discontinued treatment with LTOT within 90 days of initiation, not due to improving oxygenation or change of treatment modality, were identified. The risk of hospitalization and death as a composite outcome, and the risks of individual outcomes of hospitalization and death, were compared with age-, sex- and disease type-matched controls who continued LTOT, using Cox regression adjusted for confounders. Results: In total, 79 patients discontinuing LTOT and 395 controls were analyzed, both groups with a mean age of 73 (SD ± 11) years, 72% females, 65% underlying COPD. In adjusted Cox regression models, discontinuing LTOT was not associated with an increased risk of hospitalization or death (hazard ratio (HR) 1.0 95% Confidence interval (CI) 0.78–1.3), hospitalization (HR 0.99 95% CI 0.75–1.3), or death (HR 0.79 95% CI 0.61-1.0). Conclusion: In this study, patients fulfilling LTOT initiation criteria who discontinued therapy were not found to be at an increased risk of hospitalization or death, suggesting equipoise for a randomized trial of LTOT discontinuation or non-initiation in selected patient groups.
- Open Access
- 5 November 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 250, 108469
Corrigendum to “Respiratory symptoms, lung function, and fraction of exhaled nitric oxide before and after assignment in a desert environment—a cohort study” [Respir. Med. J. (2021 Nov–Dec) 189 106643, E-pub 2021 Oct 8]
- 5 November 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 250, 108469
Open AccessCorrigendum to “Respiratory symptoms, lung function, and fraction of exhaled nitric oxide before and after assignment in a desert environment—a cohort study” [Respir. Med. J. (2021 Nov–Dec) 189 106643, E-pub 2021 Oct 8]